June 18, 2024 03:49 PM EDT
Pharma
Cell/Gene Tx
FDA+

In­ter­na­tion­al so­ci­ety crit­i­cizes Utah law for per­mit­ting un­ap­proved stem cell ther­a­pies

Lia DeGroot

The In­ter­na­tion­al So­ci­ety for Cell and Gene Ther­a­py is push­ing back against a Utah law that al­lows health­care providers to treat pa­tients with pla­cen­tal stem …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times